Map. Microbiome data shows which microbial functions differ in a given health area.
Partnerships
Microbiome formulations, designed in simulation and taken into clinical study, licensed for your brand.
Enbiosis designs food-grade blends with its Digital Twin & AI Engine and takes its formulations into registered clinical studies. We license the formulation and supply the active blend to food, beverage and nutraceutical companies, scoped by formulation, category and territory.
- Six formulation studies registered on ClinicalTrials.gov
- Five randomised, placebo-controlled studies in progress
- Licence, blend supply and royalty in one agreement
For companies that want a formulation with a clinical programme behind it
You bring the brand, the format and the route to market. We bring a formulation designed around a biological target, the study programme behind it and the active blend itself.
Product categories
- Capsules and powders
- Dairy and fermented products
- Bars and functional foods
- Beverages and shots
Your team, our answers
R&D: dose per serving, processing, shelf life and sensory, planned together for your matrix.
Brand: a distinct gut-axis story, co-branding and exclusivity by territory.
Regulatory: registered study designs, ingredient information and a market-by-market claim pathway.
Procurement: neutral premix supply at cost-plus under one agreement.
Looking to distribute a finished Enbiosis product instead? See our formulations.
We start from the outcome, not from an ingredient
Model. The Digital Twin & AI Engine simulates how gut microbial communities respond to combinations of food-grade inputs.
Select. The engine works backwards from the target to the smallest set of prebiotic and postbiotic inputs predicted to reach it, and the blend then enters clinical study.
The clinical programme, as registered
These are the Enbiosis formulation studies registered to date. Each row links to the public registry entry, where the study population, endpoints and timelines are described in full.
Ocular surface
- Design
- Single-arm, open-label pilot
- Participants
- 20
- Status
- Completed March 2026, results not yet published
- Registry
- NCT07148271
Ocular surface
- Design
- Randomised, quadruple-masked, placebo-controlled
- Participants
- 130 (planned)
- Status
- Enrolling by invitation
- Registry
- NCT07453212
Metabolic health
- Design
- Randomised, quadruple-masked, placebo-controlled, 24 weeks
- Participants
- 100 (planned)
- Status
- Recruiting
- Registry
- NCT07622628
Gut health
- Design
- Randomised, quadruple-masked, placebo-controlled, multicentre
- Participants
- 162 (planned)
- Status
- Not yet recruiting
- Registry
- NCT07619638
Weight management
- Design
- Randomised, quadruple-masked, placebo-controlled, 12 weeks
- Participants
- 80 (planned)
- Status
- Enrolling by invitation
- Registry
- NCT07736547
Men's health
- Design
- Randomised, triple-masked, placebo-controlled, 12 weeks
- Participants
- 112 (planned)
- Status
- Enrolling by invitation
- Registry
- NCT07761546
No formulation results have been published yet; we will add them here as they are reported, whatever the outcome. All six studies use sachet or finished-supplement formats. Separately, our scientific team has published peer-reviewed clinical research on AI-personalised diets in The American Journal of Gastroenterology and Gut Microbes; those studies did not test an Enbiosis formulation.
Last updated
Formulations open for licensing
Gut-eye axis
en-TEAR
A prebiotic formulation designed around the relationship between the gut microbiome and the ocular surface. Contains no omega-3s, vitamins or lutein. On the market in Türkiye as a finished 8-week programme.
Clinical status: completed single-arm pilot (NCT07148271); randomised, placebo-controlled study in progress (NCT07453212).
Gut-metabolic axis
en-JOY&FIT
A formulation designed around the relationship between the gut microbiome and metabolism, built as a 90-day programme.
Clinical status: shared in the evidence pack.
Claim note: authorised claims depend on the final composition in each market.
Gut-skin axis
en-CLEAR
A formulation designed around the relationship between the gut microbiome and the skin.
Clinical status: a product-specific study is not yet registered; it will be listed here once it is.
Claim note: authorised claims depend on the final composition in each market.
Gut-hormone axis
en-MASCULINE
A formulation for men, designed around the relationship between the gut microbiome and hormonal balance. Not suitable for individuals under 18 years of age.
Clinical status: shared in the evidence pack.
Claim note: authorised claims depend on the final composition in each market.
From our blend to your product
Capsules and powders. The format closest to our clinical studies.
Dairy and fermented products. Yoghurt, kefir and fermented drinks, assessed per formulation.
Bars and functional foods. Assessed for processing conditions and dose per serving.
Beverages and shots. Assessed for stability and sensory profile.
The active blend is supplied as a neutral premix. Suitability for each format is confirmed per formulation in a joint feasibility plan. We do not assume that a result in one format applies to another.
What your R&D team receives after NDA
- Formulation rationale and technical dossier
- Premix specification and certificate of analysis
- Ingredient information for your regulatory filing
One agreement, three parts
Licence fee. Upfront access to the formulation, its know-how and the technical dossier.
Active blend supply. Per-unit premix supply at cost-plus pricing.
Sales royalty. A percentage of net sales of products that contain the blend.
Scope: Each licence is set by formulation, product category and territory. Exclusivity is available.
Co-branding: Your product can carry the Powered by Enbiosis mark, with usage terms defined per market in the agreement.
How licensing works
Explore. Sign a mutual NDA and receive the partner evidence pack: formulation rationale, study registrations and protocol summaries, specification and regulatory notes.
Scope. Choose the formulation, product category and territory, and whether you need exclusivity.
Feasibility. Your R&D team and ours test the blend in your matrix against an agreed plan for dose per serving, processing, shelf life and sensory.
Agreement. Licence fee, active blend supply and royalty, in one contract.
Launch. You manufacture and market under your brand, with the option to carry the Powered by Enbiosis mark. We share study updates as they are reported.
Evidence and regulatory pathway, stated plainly
A registered study is not a result, and a study in one format does not automatically carry over to another. Claims depend on the market, the product category and the final composition. In the EU and UK, consumer health claims must come from the authorised register and meet its conditions; in the US, the rules differ for foods and dietary supplements; in Türkiye, food supplements need Ministry approval before sale. We map the claim and filing pathway for each market with your regulatory team.
The team behind the engine
Enbiosis was founded in 2019 by Ömer Özkan (CEO), Özkan Ufuk Nalbantoğlu (CTO) and Aycan Gündoğdu, bringing together microbiome science, computational biology and nutrition research. The company operates through Enbiosis Biotechnology Limited (England and Wales, company number 13111010) and Enbiosis Biyoteknoloji A.Ş. in Türkiye.
Recognition
- UK Tech Rocketship Awards, Gold, Digital Health, 2022
- Global Food Tech Awards 2026, EMEA heat, Top 10 finalist
- The Longevity Show 2026 Pitch Competition, Top 5 finalist
FAQ
What evidence exists for your formulations today?
Six formulation studies are registered on ClinicalTrials.gov: one completed single-arm pilot, not yet published, and five randomised, placebo-controlled studies in progress. No formulation results have been published yet. The registry numbers are listed above so your team can review designs and timelines directly.
Does evidence from a sachet apply to a yoghurt, bar or drink?
Not automatically. Processing, the food matrix and dose per serving can change how an ingredient behaves. For each food format we agree with your R&D and regulatory teams what data is needed before launch.
Which health claims can we make on our product?
That depends on the market, the product category and the final composition. A clinical study does not grant a claim by itself. We review the pathway for each market with your regulatory team.
Is a notification or approval needed?
Often, yes. It depends on whether the product is a food supplement or a conventional food, and on the market. We provide the ingredient and specification information your regulatory team needs to file.
The study populations are defined by a health condition. Does that matter for a general-population product?
Yes. The populations are described in each registry entry, and communication aimed at the general population needs its own assessment for each market.
What exactly do we license, and what protects it?
The formulation, its know-how and the technical dossier, together with supply of the active blend. Patent applications have been filed; the scope of the licensed intellectual property is set out in writing during due diligence.
Can we get exclusivity?
Yes. Exclusivity can be agreed by formulation, product category and territory.
Which party manufactures the finished product?
You do, in your own facilities or with your co-manufacturer. We supply the active blend and support integration.
Which Enbiosis company do we contract with?
This is confirmed in the agreement, based on your territory and the supply route.
Start with the evidence pack
Tell us your category, target markets and timeline. We will send a mutual NDA and the partner evidence pack, then set up a call with our R&D and partnerships team.
This page is intended for business partners. Product status and permitted claims vary by market.